Endometrial Gene Expression Profile in Controlled Ovarian Stimulation

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Previous studies have suggested that premature luteinization (PL)during controlled ovarian stimulation (COS) decreases the implantation rate due to a negative effect on the endometrium receptivity. This study aims to describe the impact on endometrial gene expression of PL in GnRH antagonist and GnRH agonist cycles.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00455949` - Effect of Premature Luteinization on the Oocyte Quality in Oocyte Donation Program.	N/A

NCT number	NCT00447850
Study type	Interventional
Source	Instituto Valenciano de Infertilidad, IVI VALENCIA
Contact
Status	Completed
Phase	N/A
Start date	April 2007
Completion date	July 2009

Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms